AI-Driven Precision Medicine Market Likely to reach ~USD 10 billion by 2035.
An extensive study of propelling opportunities in, “AI-Driven Precision Medicine Market Size, Share, Growth Opportunity Analysis Report by Technology Type (Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), Computer Vision, Reinforcement Learning, Big Data Analytics, Others), Component, Data Type, Delivery Mode, Therapeutic Area, Application, End-user and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A comprehensive report of growing market landscapes in the AI-driven precision medicine sector uncovering key growth drivers including niche market leadership, technology-enabled distribution, and increasing consumer needs supporting AI-driven precision medicine potential to scale globally.
AI-Driven Precision Medicine Market Forecast 2035:
According to the report, the AI-driven precision medicine market is anticipated to grow from USD 0.7 Billion in 2025 to USD 9.7 Billion in 2035 at an impressive CAGR of 26.8% during the forecast. Growing demand for personalized therapies, faster diagnoses, and a global shift toward value in healthcare are some of the key drivers of the AI-led precision medicine market. Specifically, in cancer, genetic diseases, and chronic diseases, AI provides physicians with the ability to assess disease risk, select the appropriate therapeutic intervention, and track and monitor their patient's outcomes. AI offers data-driven healthcare; with better outcomes and fewer side effects, it allows patients and providers to move away from trial and error therapies. New AI products were introduced in Europe and North America in 2024 and 2025 that combine genomic testing, digital imaging, and clinical records to provide information in real time. For example, Tempus launched SmartPath, enabling physicians to change a cancer patient's treatment plan remotely and in real-time.
Similarly, new products such as PathAI and Paige enhance cancer accuracy of diagnosis through biopsy images, producing less inaccurate results, and saving time. These emerging innovations are providing opportunities for AI development across the spectrum of healthcare, from large hospitals, to small clinics, to home care. However, the market continues to face challenges. Slow uptake is due in part to expensive technology, stringent data privacy laws, and poor access to digital health infrastructure, particularly in low-resource settings.
Moreover, many countries also do not have specific policies to regulate how artificial intelligence tools are able to operate in healthcare and to what extent. As companies and governments continue to invest in safe, understandable, and scalable artificial intelligence, the possibilities for expansion are substantial. Increased connectivity, real world data, and mobile technologies are driving artificial intelligence in precision medicine wellness initiatives and making them more universally available for people from children to older patients and across several diseases.
“Key Driver, Restraint, and Growth Opportunity Defining the Neurostimulation Devices Market
AI-enabled precision medicine is becoming increasingly commonplace, particularly as research expands in cancer, rare diseases, and genetic disorders. As many patients are ill-suited to one-size-fits-all treatments, physicians have begun utilizing AI tools to assess disposition patients for the best possible care, by comparing genetic, lifestyle, health, and demographic information. Companies like Tempus and PathAI are leading the charge by developing machine-learning that can match patients to the correct treatment, and reduce the time and distance to this care process.
Despite the promising developments in the field of AI supported precision medicine, the equitable access to tools and technology remain questionable. It is even less equitable in low-income communities, urban underserved or rural communities, or hospitals where the available funds and infrastructure allows for either limited digital integrated funding or resources do not permit AI. Some health care providers would not have the training needed to use these AI systems regardless of the digital endowment; additionally, issues persist in a) interpretation of patient privacy, b) intellectual property to protect AI or c) acceptable reimbursement schematic. These areas of unclear policy create a lag in administrative and resource development leading to a digital divide between traditionally high resource/high-tech care patterns in certain regions and the care in under-resourced regions.
While many invasiveness to healthcare and precision medicine are still to be determined, the outlook is better than ever. AI permits for much more personalized care and proactive care. Real-time clinical decision platforms, AI-enabled diagnostic tools, and wearable sensors that can collect data and feed that data back into treatment models are all helping clinicians to make better and faster decisions. With these tools becoming more user-friendly, lower cost, and embedded into every healthcare system, they seek to give patients easier and more profitable precision medicine while also affording patients things like early diagnosis, targeted treatment, and better outcomes in the future.
Expansion of AI-Driven Precision Medicine Market
"Universal Access, Aging Population, and Innovation Fuel the Diverse Growth of the AI-Driven Precision Medicine Market"
Regional Analysis of AI-Driven Precision Medicine Market
Prominent players operating in the AI-driven driven precision medicine market include Berg Health, Butterfly Network, Caption Health, Flatiron Health (Roche), Foundation Medicine (Roche), Freenome, Genalyte, Google Health / DeepMind, Guardant Health, IBM Watson Health, Microsoft Healthcare (AI for Health), NVIDIA Corporation, Oracle Health Sciences, Owkin, Paige AI, PathAI, Philips Healthcare, Siemens Healthineers, Tempus Labs, Zebra Medical Vision, Other key Players.
The AI-driven precision medicine has been segmented as follows:
AI-Driven Precision Medicine Market Analysis, by Technology Type
AI-Driven Precision Medicine Market Analysis, by Component
AI-Driven Precision Medicine Market Analysis, by Data Type
AI-Driven Precision Medicine Market Analysis, by Delivery Mode
AI-Driven Precision Medicine Market Analysis, by Therapeutic Area
AI-Driven Precision Medicine Market Analysis, by Application
AI-Driven Precision Medicine Market Analysis, by End-User
AI-Driven Precision Medicine Market Analysis, by Region
About Us
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
Contact US
USA Address:
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
info@marketgenics.co
India Address:
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
+91-8788594158
sales@marketdigits.co
Table of Contents
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation